From KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies
{{output}}
Background: KRAS is a central oncogenic driver in multiple solid malignancies, including non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. Activating KRAS mutations, together with co-mutations a... ...
